retatrutide clinical trial phase Retatrutide is among a new class of weight loss drugs being tested for their effectiveness

Retatrutide, an experimental drug currently in Phase 3 clinical trials, is nicknamed the Godzilla of weight-loss jabs because of its potential superior efficacy. Developed by Eli Lilly, retatrutide is a triple hormone

25.66

★★★★☆4.8 (126)

Today we shared new results on retatrutide, an investigational, first-of-its-kind treatment we're studying in adults with obesity or overweight with at least one weight-related comorbidity. Read more about the Phase 3 findings:

21.76

★★★★★4.9 (98)

Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial

23.79

★★★★★5.0 (157)

New Weight Loss Drug Retatrutide: My Patient's 85-Pound Journey (And What the Trials Don't Tell You)

28.65

★★★★★4.7 (84)

Today's TRIUMPH-4 results are a clear signal: the next generation of incretin medications will be more powerful than anything we've seen before. Retatrutide is showing nearly 30% body-weight reduction in clinical trials,

20.13

★★★★★4.9 (203)

Retatrutide—A Game Changer in Obesity Pharmacotherapy

28.48

★★★★★5.0 (176)

Reta clinical trial data & dosing — a must read Retatrutide (Reta) isn't just another GLP-1. It's a triple-agonist peptide studied in Phase 3 trials for metabolic health — targeting GLP-1, GIP,

27.26

★★★★★4.8 (132)